8-K filing — ADIAL PHARMACEUTICALS, INC. (ADIL)
Filed: 2026-08-25 AccNo: 0001213900-26-093544 Size: 188 KB Item 3.02: Unregistered Sales of Equity Securities
Read original at edgarStocks · News reference
8-K filing — ADIAL PHARMACEUTICALS, INC. (ADIL)
Filed: 2026-08-21 AccNo: 0001213900-26-092690 Size: 195 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 21, 2026, 9:17 PM
- Checked
- Aug 21, 2026, 9:17 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Adial Pharmaceuticals shares are trading lower after the company reported a wider net loss for the second quarter.
Read original at benzingaAdial Pharmaceuticals Q2 EPS $(11.25)
Read original at benzingaAdial Pharmaceuticals Says As Of Aug 10, Anticipates Termination Of CEO Cary Claiborne After 2026 Annual Meeting; Anticipates Matthew Davidson To Be Appointed President And CEO; Anticipates Termination Of CFO Vinay Shah After 2026 Annual Meeting; Anticipates Board Changes And Legacy Member Resignations
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As of August 10, 2026, Adial Pharmaceuticals, Inc. (the
Read original at benzinga